Abraxane and Temodar Plus Genasense in Advanced Melanoma
Status:
Unknown status
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety, efficacy, pharmacokinetics, and
pharmacodynamics of combination treatment with Temodar®, Genasense®, and Abraxane® in
chemotherapy-naïve subjects with advanced melanoma and normal lactate dehydrogenase (LDH).